Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Holtzman

Showing results (71-80 of 602) with videos related to

Pageof 61
Sort By:
Nature|December 15, 2018
Amyloid-β 'seeds' in old vials of growth hormoneTien-Phat V Huynh, David M Holtzman
Science Translational Medicine|December 13, 2019
Dementia is not synonymous with Alzheimer's diseaseClifford R Jack, David M Holtzman, Reisa Sperling
JAMA Neurology|July 6, 2021
APOE ε4 Association With Cognition and Alzheimer Disease Biomarkers in Down Syndrome-Implications for Clinical Trials and Treatments for AllCynthia A Lemere, Elizabeth Head, David M Holtzman
Neuron|August 15, 2009
The role of apolipoprotein E in Alzheimer's diseaseJungsu Kim, Jacob M Basak, David M Holtzman
Cold Spring Harbor Perspectives in Medicine|November 6, 2012
Alzheimer disease in 2020David M Holtzman, Eckhard Mandelkow, Dennis J Selkoe
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|July 4, 2024
An emerging role for the gut microbiome in tauopathyYiyang Zhu, Wade K Self, David M Holtzman
The Journal of Experimental Medicine|July 20, 2016
Changes in insulin and insulin signaling in Alzheimer's disease: cause or consequence?Molly Stanley, Shannon L Macauley, David M Holtzman
Nature Immunology|June 29, 2026
Adaptive immunity in the pathogenesis of neurodegenerationYongyi Li, Jason D Ulrich, David M Holtzman
Developmental Neuroscience|March 18, 2003
Evidence that p38 mitogen-activated protein kinase contributes to neonatal hypoxic-ischemic brain injuryByung Hee Han, Junjeong Choi, David M Holtzman
Annals of Neurology|March 15, 2023
Lecanamab Ushers in a New Era of Anti-Amyloid Therapy for Alzheimer's DiseaseErik S Musiek, Eric McDade, David M Holtzman
Pageof 61

Showing results (71-80 of 602) with videos related to

Sort By:
Pageof 61
Nature|December 15, 2018
Amyloid-β 'seeds' in old vials of growth hormoneTien-Phat V Huynh, David M Holtzman
Science Translational Medicine|December 13, 2019
Dementia is not synonymous with Alzheimer's diseaseClifford R Jack, David M Holtzman, Reisa Sperling
JAMA Neurology|July 6, 2021
APOE ε4 Association With Cognition and Alzheimer Disease Biomarkers in Down Syndrome-Implications for Clinical Trials and Treatments for AllCynthia A Lemere, Elizabeth Head, David M Holtzman
Neuron|August 15, 2009
The role of apolipoprotein E in Alzheimer's diseaseJungsu Kim, Jacob M Basak, David M Holtzman
Cold Spring Harbor Perspectives in Medicine|November 6, 2012
Alzheimer disease in 2020David M Holtzman, Eckhard Mandelkow, Dennis J Selkoe
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|July 4, 2024
An emerging role for the gut microbiome in tauopathyYiyang Zhu, Wade K Self, David M Holtzman
The Journal of Experimental Medicine|July 20, 2016
Changes in insulin and insulin signaling in Alzheimer's disease: cause or consequence?Molly Stanley, Shannon L Macauley, David M Holtzman
Nature Immunology|June 29, 2026
Adaptive immunity in the pathogenesis of neurodegenerationYongyi Li, Jason D Ulrich, David M Holtzman
Developmental Neuroscience|March 18, 2003
Evidence that p38 mitogen-activated protein kinase contributes to neonatal hypoxic-ischemic brain injuryByung Hee Han, Junjeong Choi, David M Holtzman
Annals of Neurology|March 15, 2023
Lecanamab Ushers in a New Era of Anti-Amyloid Therapy for Alzheimer's DiseaseErik S Musiek, Eric McDade, David M Holtzman
Pageof 61